[
    [
        {
            "time": "2021-11-09",
            "original_text": "Canada grants interim authorization to Eli Lilly's COVID-19 antibody drug",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "COVID-19",
                    "antibody drug",
                    "interim authorization"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Canada grants interim authorization to Eli Lilly's COVID-19 antibody drug",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-09",
            "original_text": "U.S. sees spike in daily COVID-19 cases, hospitalizations surge",
            "features": {
                "keywords": [
                    "U.S.",
                    "spike",
                    "COVID-19 cases",
                    "hospitalizations"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "U.S. sees spike in daily COVID-19 cases, hospitalizations surge",
                "Correlation": 5,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-09",
            "original_text": "Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19",
            "features": {
                "keywords": [
                    "Lilly",
                    "neutralizing antibody",
                    "bamlanivimab",
                    "interim authorization",
                    "Health Canada",
                    "COVID-19"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-09",
            "original_text": "Eli Lilly: Back From the Depths",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Back From the Depths"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly: Back From the Depths",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-11-09",
            "original_text": "Lilly/Incyte's Olumiant Gets FDA Emergency Nod for COVID-19",
            "features": {
                "keywords": [
                    "Lilly/Incyte",
                    "Olumiant",
                    "FDA",
                    "Emergency Nod",
                    "COVID-19"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly/Incyte's Olumiant Gets FDA Emergency Nod for COVID-19",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-09",
            "original_text": "Pharma Stock Roundup: PFE COVID-19 Vaccine Final Analysis, FDA Updates & More",
            "features": {
                "keywords": [
                    "Pharma Stock",
                    "PFE",
                    "COVID-19 Vaccine",
                    "Final Analysis",
                    "FDA Updates"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: PFE COVID-19 Vaccine Final Analysis, FDA Updates & More",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-09",
            "original_text": "Eli Lilly Gets FDA Approval For COVID Treatment, WHO Doubts Gilead's Remdesivir",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "FDA Approval",
                    "COVID Treatment",
                    "WHO",
                    "Gilead",
                    "Remdesivir"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly Gets FDA Approval For COVID Treatment, WHO Doubts Gilead's Remdesivir",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-09",
            "original_text": "Lilly's arthritis drug and Gilead's Veklury receive FDA authorization as combination COVID-19 treatment",
            "features": {
                "keywords": [
                    "Lilly",
                    "arthritis drug",
                    "Gilead",
                    "Veklury",
                    "FDA authorization",
                    "combination",
                    "COVID-19 treatment"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Lilly's arthritis drug and Gilead's Veklury receive FDA authorization as combination COVID-19 treatment",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-09",
            "original_text": "The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger",
            "features": {
                "keywords": [
                    "Daily Biotech Pulse",
                    "Amarin",
                    "Vascepa Data",
                    "Mesoblast",
                    "Novartis Deal",
                    "Decision Day",
                    "Eiger"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-11-09",
            "original_text": "Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement",
            "features": {
                "keywords": [
                    "Lilly",
                    "Precision BioSciences",
                    "Genome Editing",
                    "Research Collaboration",
                    "License Agreement"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-09",
            "original_text": "Eli Lilly’s Baricitinib Gets FDA Approval for Emergency Use with Remdesivir to Treat COVID-19 Patients",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Baricitinib",
                    "FDA Approval",
                    "Emergency Use",
                    "Remdesivir",
                    "COVID-19 Patients"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Eli Lilly’s Baricitinib Gets FDA Approval for Emergency Use with Remdesivir to Treat COVID-19 Patients",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-09",
            "original_text": "Eli Lilly's Arthritis Drug Gets Emergency Use Approval For Treatment Of COVID-19",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Arthritis Drug",
                    "Emergency Use Approval",
                    "Treatment",
                    "COVID-19"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Eli Lilly's Arthritis Drug Gets Emergency Use Approval For Treatment Of COVID-19",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]